Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the biggest names in the biotechnology sector. The company has already-approved assets (of which there are six so far) and pipeline-based development drugs (of which there are around 15 right now) designed to target a whole host of different indications, from eye disease to heart disease, to pain, cancer, infectious diseases and rare diseases.
Oil prices have continued their volatility after news broke that the EIA (Energy Information Administration) released generally mixed oil-related data for the prior week and after an interesting rig count update. In what follows, I will go over the data released by both the EIA and Baker Hughes (NYSE:BHI) and give my own thoughts on what it means for investors in companies like Memorial Production....More>>>
While most income investors are reaching for big yields right now, a small group of “hidden yield” stocks are quietly handing smart investors growing income streams plus annual returns of 12%, 27.1% and even 54% or more per year.
Why wouldn’t U.S. stocks rally, surging to the biggest weekly gain in a year, amid earnings euphoria like this? With no hint of fatigue, the S&P 500 Index spent the holiday-shortened week rolling past 2,700, while the Dow Jones Industria